Skip to main content
. 2014 Jun 14;20(22):6932–6938. doi: 10.3748/wjg.v20.i22.6932

Table 2.

Baseline characteristics according to first line therapies n (%)

Standard triple therapy Bismuth quadruple therapy Sequential therapy Concomitant therapy P value1
Mean age ± SD (yr) 58.1 ± 11.6 58.5 ± 11.4 56.1 ± 11.5 56.9 ± 11.3 0.591
Male/Female (n) 72/86 10/18 20/21 24/13 0.150
Smoking (n) 28 (17.7) 4 (13.8) 8 (19.5) 8 (21.6) 0.904
Alcohol (n) 35 (22.2) 7 (24.1) 10 (24.4) 10 (27) 0.851
HTN (n) 34 (21.5) 5 (17.2) 6 (14.6) 4 (10.8) 0.451
DM (n) 14 (8.9) 3 (10.3) 2 (4.9) 2 (5.4) 0.845
Endoscopic finding (n) -
DU/GU 55 1 6 8 -
CAG 66 18 13 12 -
IM 23 1 5 3 -
Erosive gastritis 30 9 18 15 -
MALT lymphoma 0 0 2 0 -
1

Pearson's χ2 test. HTN: Hypertension; DM: Diabetes mellitus; DU: Duodenal ulcer; GU: Gastric ulcer; CAG: Chronic atrophic gastritis; IM: Intestinal metaplasia; MALT: Mucosa associated lymphoid tissue.